BBS

Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update

Retrieved on: 
Tuesday, August 1, 2023

-- Enrollment ongoing in pivotal Phase 3 trial evaluating setmelanotide in hypothalamic obesity; based on rapid progress, study now expected to be fully enrolled by the end of 2023 --

Key Points: 
  • ET --
    BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today reported financial results and provided a business update for the second quarter ended June 30, 2023.
  • R&D Expenses: R&D expenses were $33.5 million in the second quarter of 2023, as compared to $31.5 million in the second quarter of 2022.
  • S,G&A Expenses: S,G&A expenses were $30.0 million for the second quarter of 2023, as compared to $22.3 million for the second quarter of 2022.
  • ET today to review its second quarter 2023 financial results and recent business activities.

Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome

Retrieved on: 
Wednesday, July 19, 2023

“These results demonstrate that hyperphagia and severe obesity associated with BBS negatively affect performance in school, work and social relationships.

Key Points: 
  • “These results demonstrate that hyperphagia and severe obesity associated with BBS negatively affect performance in school, work and social relationships.
  • Caregivers of patients with BBS reported that hyperphagia has broad impacts, well beyond contributing to obesity.
  • Hyperphagia had at least a moderate negative impact on most patients’ mood/emotions (56%), sleep (54%), school (57%), leisure (62%), and familial relationships (51%).
  • “ Caregiver Burden in Bardet-Biedl Syndrome: Findings from the CARE-BBS Study ,” quantifies caregiver burden associated with obesity and hyperphagia.

EQT Private Equity to sell BBS Automation, a global leader in factory automation solutions

Retrieved on: 
Tuesday, June 13, 2023

EQT Private Equity partnered with Josef Wildgruber in May 2018 and acquired a majority stake in BBS with a joint vision to build a leading global platform for factory automation.

Key Points: 
  • EQT Private Equity partnered with Josef Wildgruber in May 2018 and acquired a majority stake in BBS with a joint vision to build a leading global platform for factory automation.
  • By combining the Dürr automation business with BBS' global automation platform, we are creating a global leader in the field.
  • We have transformed BBS to a global leader in industrial automation by expanding its solutions portfolio, end markets, and geographic footprint."
  • Josef Wildgruber, CEO and Founder of BBS Automation, said "This is a momentous day in the history of BBS.

Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries

Retrieved on: 
Monday, May 22, 2023

Under the terms of this exclusive agreement, Genpharm will distribute IMCIVREE to patients in GCC countries for the treatment of hyperphagia and obesity due to Bardet-Biedl syndrome (BBS) or genetically-confirmed biallelic pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency.

Key Points: 
  • Under the terms of this exclusive agreement, Genpharm will distribute IMCIVREE to patients in GCC countries for the treatment of hyperphagia and obesity due to Bardet-Biedl syndrome (BBS) or genetically-confirmed biallelic pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency.
  • IMCIVREE is approved for these indications in the United States, Canada, the United Kingdom and the European Union.
  • Providers in the region now have the ability to prescribe IMCIVREE to qualifying patients who they believe will benefit from the therapy.
  • “Due to many factors, GCC countries have an increased prevalence of certain genetic diseases, creating a significant demand for precision therapies, like IMCIVREE, that address illnesses at their root cause,” said Kamel Ghammachi, Genpharm Chairman.

Supply Chain Innovation Technology Company Trendsi Appoints Head of North America Logistics

Retrieved on: 
Tuesday, May 16, 2023

SHANGHAI, May 15, 2023 /PRNewswire/ -- U.S. supply chain innovation technology company Trendsi announces the appointment of Zhi Zhang as Head of North America Logistics.

Key Points: 
  • SHANGHAI, May 15, 2023 /PRNewswire/ -- U.S. supply chain innovation technology company Trendsi announces the appointment of Zhi Zhang as Head of North America Logistics.
  • Now, with Trendsi, Zhang is applying data intelligence to build a flexible supply chain and logistics infrastructure and is dedicated to filling the gaps in manufacturing automation.
  • Zhang is impressed by China's advanced flexible supply chain and well-established e-com fulfillment logistics infrastructure, which is already in place.
  • However, Zhang's expertise lies in his innovative use of logistics data analysis, which has enabled intelligent logistics operations for the entire supply chain, resulting in a more flexible, proactive, and efficient logistics system for Trendsi.

Dr. George Lam Officially Joins VSFG as Honorary Chairman

Retrieved on: 
Tuesday, May 16, 2023

HONG KONG, May 16, 2023 - (ACN Newswire) - To drive the strategic development of innovative financial services, Venture Smart Financial Holdings Limited (hereinafter referred to as "VSFG" or "the Group") officially announced the appointment of Dr. George Lam, BBS, JP ("Dr. Lam") as Honorary Chairman today.

Key Points: 
  • HONG KONG, May 16, 2023 - (ACN Newswire) - To drive the strategic development of innovative financial services, Venture Smart Financial Holdings Limited (hereinafter referred to as "VSFG" or "the Group") officially announced the appointment of Dr. George Lam, BBS, JP ("Dr. Lam") as Honorary Chairman today.
  • Dr. Lam said, "I have accepted the invitation from Mr. Lawrence Chu, Chairman of VSFG, because we share the same vision for the future development of Hong Kong's financial industry.
  • VSFG is the first virtual asset manager in Hong Kong licensed by the Hong Kong Securities and Futures Commission ("SFC").
  • Mr. Lawrence Chu, Chairman of VSFG, also expressed his sincere appreciation to Dr. Lam for joining and supporting VSFG, "As a farsighted visionary, Dr. Lam has always been driving the integration of the new and traditional economies without neglecting the importance of regulations and corporate governance.

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency

Retrieved on: 
Monday, May 8, 2023

BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company, today announced that Health Canada has approved IMCIVREE® (setmelanotide solution for subcutaneous injection) for weight management in adult and pediatric patients 6 years of age and older with obesity due to Bardet-Biedl syndrome (BBS) or genetically-confirmed biallelic pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency due to variants interpreted as pathogenic, likely pathogenic, or of uncertain significance. Please consult the IMCIVREE product monograph available at www.rhythmtx.ca.

Key Points: 
  • Setmelanotide has been shown to reduce the weight of patients living with BBS or POMC, PCSK1 or LEPR deficiency.
  • The trials met all primary endpoints and key secondary endpoints among patients at 52 weeks on therapy.
  • Results from these trials were featured in several publications, including the peer-reviewed journal The Lancet Diabetes and Endocrinology .
  • The most common adverse reactions were skin hyperpigmentation, injection site reactions and nausea.

Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update

Retrieved on: 
Tuesday, May 2, 2023

-- Management to host conference call today at 8:00 a.m. ET --

Key Points: 
  • ET --
    BOSTON, May 02, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today reported financial results and provided a business update for the first quarter ended March 31, 2023.
  • R&D Expenses: R&D expenses were $37.9 million in the first quarter of 2023, as compared to $32.5 million in the first quarter of 2022.
  • S,G&A Expenses: S,G&A expenses were $24.6 million for the first quarter of 2023, as compared to $21.4 million for the first quarter of 2022.
  • ET today to review its first quarter 2023 financial results and recent business activities.

Broad Arrow and Hagerty Marketplace Launch Retro Motors Collection - Now Available for Online Bidding

Retrieved on: 
Thursday, April 27, 2023

The Retro Motors Collection launches today on Hagerty Marketplace with online auctions presented in a rolling format, with a handful of cars opening for bidding daily.

Key Points: 
  • The Retro Motors Collection launches today on Hagerty Marketplace with online auctions presented in a rolling format, with a handful of cars opening for bidding daily.
  • Offered by a lifelong, passionate enthusiast who has been buying and selling collector cars for decades, each car from The Retro Motors Collection has been inspected and cataloged by a Hagerty Marketplace specialist.
  • Barney Ruprecht, Vice President of Auctions, Hagerty Marketplace, comments: “The Retro Motors Collection is offered by a passionate enthusiast and friend of Hagerty and Broad Arrow who has been collecting his entire adult life.
  • More information on how to register to bid and sell on Hagerty Marketplace online auctions can be found at the website: Hagerty Marketplace .

Hagerty Marketplace Brings Retro Motors Collection to Online Auction Platform

Retrieved on: 
Wednesday, April 26, 2023

TRAVERSE CITY, Mich., April 26, 2023 /PRNewswire/ -- Hagerty, Inc., (NYSE: HGTY) an automotive lifestyle brand and a leading specialty insurance provider, today announced the offering of Hagerty Marketplace online auction's first private collection sale. The recently launched platform allows members and enthusiasts to buy and sell automobiles through a trusted, easy-to-use system. The Retro Motors Collection comprises over 30 cars largely from the 1950s through today, with a focus on American muscle and high-powered European sports cars. 

Key Points: 
  • The Retro Motors Collection will launch on Hagerty Marketplace online auctions beginning Monday, May 15 in a rolling format, with a handful of cars opening for bidding daily and closing five days following each launch.
  • Offered by a lifelong, passionate enthusiast who has been buying and selling collector cars for decades, each car from The Retro Motors Collection has been inspected and cataloged by a Hagerty Marketplace specialist.
  • Barney Ruprecht, Vice President of Auctions, Hagerty Marketplace, comments: "The Retro Motors Collection is offered by a passionate enthusiast and friend of Hagerty and Broad Arrow who has been collecting his entire adult life.
  • More information on how to register to bid and sell on Hagerty Marketplace online auctions can be found at the website: Hagerty Marketplace .